The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Novo Nordisk A/S

NYSE: NVO
Last

(U.S.) $44.65

Today's change-0.23 -0.51%
Updated September 26 12:05 PM EDT. Delayed by at least 15 minutes.
 

Novo Nordisk A/S

NYSE: NVO
Last

(U.S.) $44.65

Today's change-0.23 -0.51%
Updated September 26 12:05 PM EDT. Delayed by at least 15 minutes.

Novo Nordisk A/S down (U.S.)$0.23

Novo Nordisk A/S is lower today, dropping (U.S.)$0.23 or 0.51% to (U.S.)$44.65. Over the last five days, shares have lost 2.36% and sit 1.39% above their 52-week low. This security has underperformed the S&P 500 by 30.03% during the last year.

Key company metrics

  • Open(U.S.) $44.77
  • Previous close(U.S.) $44.88
  • High(U.S.) $44.84
  • Low(U.S.) $44.59
  • Bid / Ask(U.S.) $44.65 / (U.S.) $44.66
  • YTD % change-23.12%
  • Volume750,818
  • Average volume (10-day)3,093,263
  • Average volume (1-month)3,175,644
  • Average volume (3-month)2,235,266
  • 52-week range(U.S.) $44.04 to (U.S.) $59.00
  • Beta0.71
  • Trailing P/E20.99×
  • P/E 1 year forward19.68×
  • Forward PEG1.81×
  • Indicated annual dividend(U.S.) $0.91
  • Dividend yield2.03%
  • Trailing EPS(U.S.) $2.13
Updated September 26 12:05 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+32.68%

Based on its net profit margin of 32.68%, Novo Nordisk A/S is among the more effective companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.36%Sector:Industry:
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q2/2016Q1/2016Q4/2015Q3/2015
Fiscal Quarter Endvalues in $ millions unless otherwise notedJun 30, 201606/30/2016Mar 31, 201603/31/2016Dec 31, 201512/31/2015Sep 30, 201509/30/2015
Revenue27,45927,21228,87626,792
Total other revenue--------
Total revenue27,45927,21228,87626,792
Gross profit23,41422,97824,26822,945
Total cost of revenue4,0454,2344,6083,847
Total operating expense14,96214,90317,75114,812
Selling / general / administrative7,7407,6499,2037,903
Research & development3,3313,3044,0343,289
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)0000
Other operating expenses, total-154-284-94-227
Operating income12,49712,30911,12511,980
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax12,60211,95310,31410,136
Income after tax9,9689,4558,2588,383
Income tax, total2,6342,4982,0561,753
Net income9,9689,4558,2588,383
Total adjustments to net income--------
Net income before extra. items9,9689,4558,2588,383
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items9,9689,4558,2588,383
Inc. avail. to common incl. extra. items9,9689,4558,2588,383
Diluted net income9,9689,4558,2588,384
Dilution adjustment00--1
Diluted weighted average shares2,5412,5502,5512,572
Diluted EPS excluding extraordinary itemsvalue per share3.923.713.243.26
Dividends per sharevalue per share0.000.006.400.00
Diluted normalized EPSvalue per share3.923.713.243.26